Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

Blood (2016) 128 (22): 1209.

https://doi.org/10.1182/blood.V128.22.1209.1209

Published: 2016

Journal Articles

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Blood (2016) 128 (5): 686–698.

https://doi.org/10.1182/blood-2016-01-693879

Published: 2016

Includes: Supplemental data

Journal Articles

Integration of innate into adaptive immune responses in ZAP-70–positive chronic lymphocytic leukemia

Michaela Wagner, Madlen Oelsner, Andrew Moore, Frederik Götte, Peer-Hendrik Kuhn, Torsten Haferlach, Michael Fiegl, Christian Bogner, E. Joanna Baxter, Christian Peschel, George A. Follows, Ingo Ringshausen

Blood (2016) 127 (4): 436–448.

https://doi.org/10.1182/blood-2015-05-646935

Published: 2016

Includes: Supplemental data

Journal Articles

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

Thomas Köhnke, MD, Sandra Rechkemmer, Veit Leonhard Bücklein, MD, Kristina Pfannes, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2015) 126 (23): 2593.

https://doi.org/10.1182/blood.V126.23.2593.2593

Published: 2015

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

Journal Articles

ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL

Michaela Wagner, Madlen Oelsner, Peer-Hendrik Kuhn, MD, Torsten Haferlach, MD, Michael Fiegl, MD, Christian Bogner, MD, Christian Peschel, MD, Ingo Ringshausen, MD

Blood (2014) 124 (21): 1944.

https://doi.org/10.1182/blood.V124.21.1944.1944

Published: 2014

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S. Lichtenegger, Stephanie Schneider, Klaus H. Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A. Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe

Blood (2014) 123 (3): 356–365.

https://doi.org/10.1182/blood-2013-08-523548

Published: 2014

Includes: Supplemental data

Journal Articles

Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution

Maja Rothenberg-Thurley, Dr., Binje Vick, Dr., Stephanie Schneider, PhD, Bianka Ksienzyk, Philipp A Greif, MD, Michael Fiegl, MD, Marion Subklewe, MD, Wolfgang Hiddemann, M.D., Karsten Spiekermann, MD, Irmela Jeremias, MD, Klaus H. Metzeler, MD

Blood (2013) 122 (21): 49.

https://doi.org/10.1182/blood.V122.21.49.49

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Jan Boegeholz, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Stephanie Schneider, PhD, Klaus H. Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, Marion Subklewe, MD

Blood (2013) 122 (21): 239.

https://doi.org/10.1182/blood.V122.21.239.239

Published: 2013

Journal Articles

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Max Hubmann, MD, Marion Subklewe, MD, Thomas Köhnke, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Michael Fiegl, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, PhD

Blood (2012) 120 (21): 1404.

https://doi.org/10.1182/blood.V120.21.1404.1404

Published: 2012

Journal Articles

Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia.

Michael Andreeff, MD, PhD, Michael Fiegl, PhD, Marina Konopleva, MD, PhD, Borys Korchin, Kumar Kaluarachchi, PhD, William G. Bornmann, PhD, Patrick H. Guthrie, BS, Romain Harmancey, PhD, Heinrich Taegtmeyer, MD, PhD, Ismael J. Samudio, PhD

Blood (2009) 114 (22): 3779.

https://doi.org/10.1182/blood.V114.22.3779.3779

Published: 2009

Journal Articles

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Blood (2009) 113 (17): 3903–3910.

https://doi.org/10.1182/blood-2008-07-162842

Published: 2009

Journal Articles

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

Michael Fiegl, Ismael Samudio, Karen Clise-Dwyer, Jared K. Burks, Zakar Mnjoyan, Michael Andreeff

Blood (2009) 113 (7): 1504–1512.

https://doi.org/10.1182/blood-2008-06-161539

Published: 2009

Journal Articles

Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories

Michael Fiegl, Martin Erdel, Inge Tinhofer, Georg Hopfinger, Karin Eigenberger, Florian Falkner, Andreas Falkner, Yvona Brychtova, Anna Panovska, Michael Doubek, August Zabernigg, Sigrun Sodia, Helmut Mühlberger, Christa Fonatsch, Günther Gastl, Jiri Mayer, Richard Greil

Blood (2008) 112 (11): 3164.

https://doi.org/10.1182/blood.V112.11.3164.3164

Published: 2008

NARROW

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

Integration of innate into adaptive immune responses in ZAP-70–positive chronic lymphocytic leukemia

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group

Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia.

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only